Ways2Capital Reviews : Cadila Announces ANDA Approval Ahead Of Q4 Numbers

Cadila Healthcare announced that it has received final USFDA approval to market Dutasteride and Tamsulosin HCL capsules, O.5mg/0.4 mg. The combination of dutasteride and tamsulosin is a medication produced by GlaxoSmithKline (GSK) for the treatment of adult male symptomatic benign prostatic hyperplasia. It is sold under the brand name Jalyn.

Cadila will manufacture the drug at its Moraiya manufacturing facility. However, the market for the drug is not very big (~$55mn in 2017) and there are already two generic players who manufacture the same.

Cadila is also expected to announce its Q4 numbers on Friday. Revenue is expected at Rs3200cr, EBITDA at Rs804cr, and PAT at Rs538cr.

Cadila Healthcare Ltd is currently trading at Rs358.75, up Rs1.2, or 0.34%, from its previous close of Rs357.55 on the BSE.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai